The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.
Mycoplasma pneumoniae infection is a major cause of community-acquired pneumonia in children. We performed a retrospective study to evaluate the clinical impact of the timing of azithromycin treatment in children with Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.A...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5788379?pdf=render |
| _version_ | 1819020903631028224 |
|---|---|
| author | Dehua Yang Linghong Chen Zhimin Chen |
| author_facet | Dehua Yang Linghong Chen Zhimin Chen |
| author_sort | Dehua Yang |
| collection | DOAJ |
| description | Mycoplasma pneumoniae infection is a major cause of community-acquired pneumonia in children. We performed a retrospective study to evaluate the clinical impact of the timing of azithromycin treatment in children with Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.A total of 623 patients were enrolled in this study and were divided into 2 groups according to the timing of azithromycin therapy. Children who received azithromycin within 3 days (72 hours) after the onset of Mycoplasma pneumoniae pneumonia were classified into the early azithromycin treatment group (n = 174), whereas the late azithromycin treatment group (n = 449) comprised children treated with azithromycin more than 72 hours after symptom onset. We evaluated clinical prognosis according to demographic, clinical and laboratory characteristics. Although the early azithromycin treatment group exhibited a longer fever duration after azithromycin administration (7.17±4.12 versus 4.82±3.99 days, P<0.01), the total fever duration exhibited no significant difference (9.02±4.58 versus 9.57±4.91 days, P = 0.212). After azithromycin therapy, the two groups exhibited no significant differences with respect to improvements in the laboratory and radiological findings (all P>0.05).The timing of azithromycin treatment is not associated with the clinical prognosis of Mycoplasma pneumoniae pneumonia in children in high macrolide-resistant Mycoplasma pneumoniae prevalence settings. |
| first_indexed | 2024-12-21T03:58:36Z |
| format | Article |
| id | doaj.art-e86b991643a5425dad7f33f645549cb1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T03:58:36Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e86b991643a5425dad7f33f645549cb12022-12-21T19:16:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01131e019195110.1371/journal.pone.0191951The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.Dehua YangLinghong ChenZhimin ChenMycoplasma pneumoniae infection is a major cause of community-acquired pneumonia in children. We performed a retrospective study to evaluate the clinical impact of the timing of azithromycin treatment in children with Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.A total of 623 patients were enrolled in this study and were divided into 2 groups according to the timing of azithromycin therapy. Children who received azithromycin within 3 days (72 hours) after the onset of Mycoplasma pneumoniae pneumonia were classified into the early azithromycin treatment group (n = 174), whereas the late azithromycin treatment group (n = 449) comprised children treated with azithromycin more than 72 hours after symptom onset. We evaluated clinical prognosis according to demographic, clinical and laboratory characteristics. Although the early azithromycin treatment group exhibited a longer fever duration after azithromycin administration (7.17±4.12 versus 4.82±3.99 days, P<0.01), the total fever duration exhibited no significant difference (9.02±4.58 versus 9.57±4.91 days, P = 0.212). After azithromycin therapy, the two groups exhibited no significant differences with respect to improvements in the laboratory and radiological findings (all P>0.05).The timing of azithromycin treatment is not associated with the clinical prognosis of Mycoplasma pneumoniae pneumonia in children in high macrolide-resistant Mycoplasma pneumoniae prevalence settings.http://europepmc.org/articles/PMC5788379?pdf=render |
| spellingShingle | Dehua Yang Linghong Chen Zhimin Chen The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. PLoS ONE |
| title | The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. |
| title_full | The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. |
| title_fullStr | The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. |
| title_full_unstemmed | The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. |
| title_short | The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings. |
| title_sort | timing of azithromycin treatment is not associated with the clinical prognosis of childhood mycoplasma pneumoniae pneumonia in high macrolide resistant prevalence settings |
| url | http://europepmc.org/articles/PMC5788379?pdf=render |
| work_keys_str_mv | AT dehuayang thetimingofazithromycintreatmentisnotassociatedwiththeclinicalprognosisofchildhoodmycoplasmapneumoniaepneumoniainhighmacrolideresistantprevalencesettings AT linghongchen thetimingofazithromycintreatmentisnotassociatedwiththeclinicalprognosisofchildhoodmycoplasmapneumoniaepneumoniainhighmacrolideresistantprevalencesettings AT zhiminchen thetimingofazithromycintreatmentisnotassociatedwiththeclinicalprognosisofchildhoodmycoplasmapneumoniaepneumoniainhighmacrolideresistantprevalencesettings AT dehuayang timingofazithromycintreatmentisnotassociatedwiththeclinicalprognosisofchildhoodmycoplasmapneumoniaepneumoniainhighmacrolideresistantprevalencesettings AT linghongchen timingofazithromycintreatmentisnotassociatedwiththeclinicalprognosisofchildhoodmycoplasmapneumoniaepneumoniainhighmacrolideresistantprevalencesettings AT zhiminchen timingofazithromycintreatmentisnotassociatedwiththeclinicalprognosisofchildhoodmycoplasmapneumoniaepneumoniainhighmacrolideresistantprevalencesettings |